End-stage renal disease predicts complications in pacemaker and ICD implants

Area of Science:

• Cardiology
• Nephrology
• Medical Device Technology

Background:

• Patients with chronic kidney disease (CKD) experience increased morbidity after invasive procedures.
• This study investigates the hypothesis that CKD patients have higher complication rates post-device implantation compared to those with normal renal function.

Purpose of the Study:

• To compare complication rates following implantable cardioverter-defibrillator (ICD) or pacemaker implantation in patients with varying stages of chronic kidney disease (CKD) versus controls.
• To determine if the severity of CKD correlates with an increased risk of bleeding and infection after device implantation.

Main Methods:

• A retrospective review of medical records for 1,440 patients undergoing ICD or pacemaker implantation between August 2004 and August 2007.
• Estimated glomerular filtration rate (GFR) was calculated using the Cockcroft-Gault equation; patients with GFR ≥ 90 cc/min served as controls.
• Complications, including bleeding and infection, were defined and compared across different CKD stages, particularly end-stage renal disease (ESRD).

Main Results:

• Overall, 5.7% of patients experienced bleeding complications and 0.5% had infections.
• Patients with end-stage renal disease (ESRD) showed significantly higher infection rates (12.5% vs. 0.2%) and bleeding complications (21.9% vs. 3.2%) compared to controls.
• Moderate and severe CKD also demonstrated increased bleeding complication rates (7.4% and 9.8%) compared to controls (3.2%).

Conclusions:

• End-stage renal disease (ESRD) significantly elevates the risk of bleeding and device-related infections following implantation.
• The risk of these complications is directly proportional to the severity of chronic kidney disease (CKD).
• Further research is essential to develop strategies for mitigating adverse outcomes in this high-risk patient population.